We anticipate that the initial public offering price of our common stock will be between $13.00 and $15.00 per share.We have applied to list our common stock on The NASDAQ Global Market under the symbol "VCYT".We are an "emerging growth company" under applicable Securities and Exchange Commission rules and will be subject to reduced public company reporting requirements for this
Financial Condition and Results of Operations" included elsewhere in this prospectus.OverviewWe are a diagnostics company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs.
strategy includes the following key elements:•Accelerate the growth of Afirma by expanding our base of prescribing physicians and achieving broader reimbursement.•Market our novel molecular diagnostic tests as the centerpiece of a comprehensive patient-care solution.•Drive cost and capital efficiencies by offering turnkey solutions to physicians in specialty markets.•Broaden our addressable market in endocrinology by leveraging our thyroid expertise to introduce new products.•Capitalize on our demonstrated core competencies to expand molecular cytology to additional diseases.Risks Associated with Our BusinessOur business is subject to numerous risks and uncertainties, including those identified in "Risk Factors" immediately following this
if we are unable to successfully negotiate reimbursement contracts, our commercial success could be compromised.•We may experience limits on our revenue if physicians decide not to order Afirma.•The success of our relationship with Genzyme to co-promote Afirma may have a significant effect on our business.•Because we do not recognize a significant portion of our revenue on an accrual basis, our quarterly operating results are
perform our diagnostic solution would be harmed if we were required to secure a replacement.•If we are unable to support demand for Afirma or any of our future products or solutions, our business could suffer.•If the FDA were to begin regulating our tests, we could incur substantial costs and delays associated with trying to
purchase up to 705,000 additional shares of common stock.Use of proceedsWe currently intend to use the net proceeds from this offering as follows:•approximately $20.0 million for selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of our products;•approximately $20.0 million for research and development, including medical and clinical costs, related to the continued support of Afirma as well as the development of our product pipeline; and•the
results of interim periods are not necessarily indicative of the results for the entire year.Year Ended December 31,Six Months EndedJune 30,2011201220122013(In thousands, except share and per share data)(Unaudited)Statements of Operations Data:Revenue$2,645$11,628$3,947$9,452Operating expenses:Cost of revenue(1)2,9257,5843,0006,004Research and development(1)6,6806,6083,1583,912Selling and marketing(1)2,9348,4473,0455,318General and administrative(1)5,3727,9183,6185,528Total operating expenses(1)17,91130,55712,82120,762Loss from operations(15,266)(18,929)(8,874)(11,310)Interest income22——Interest expense———(5)Other income (expense), net819278—(2,070)Net loss$(14,445)$(18,649)$(8,874)$(13,385)Net loss per common share, basic and diluted$(24.90)$(28.68)$(13.90)$(16.47)Shares used in computing net loss per common share, basic and diluted580,061650,333638,318812,703Other Operating Data:Fine needle aspirations (FNAs) received6,40225,8909,53523,181(1)Includes
may never achieve or sustain profitability, and our failure to achieve and sustain profitability in the future could cause the market price of our common stock to decline.Our financial results depend solely on sales of Afirma, and we will need to generate sufficient revenue from this and other diagnostic solutions to grow our business.All of our historical revenue has been derived from the sale of Afirma, which we commercially launched in January 2011.
If our revenue or operating results fall below expectations, the price of our common stock would likely decline.We rely on sole suppliers for some of the reagents, equipment, chips and other materials used in Afirma, and we may not be able to find replacements or transition to
difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer.If the FDA were to begin regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval.Clinical laboratory tests like Afirma are regulated under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, as well as
device, we would be required to file a 510(k) application and obtain FDA clearance to use the container, which could be time consuming and expensive.We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.In addition to the need to scale our testing capacity, future growth will impose significant added responsibilities on management,
factors make the billing process complex, including:•differences between the list price for Afirma and the reimbursement rates of payers;•compliance with complex federal and state regulations related to billing Medicare;•disputes among payers as to which party is responsible for payment;•differences in coverage among payers and the effect of patient co-payments or co-insurance;•differences in information and billing requirements among payers;•incorrect or missing billing information; and•the resources required to manage the billing and claims appeals process.Additionally,
revenue or achieving profitability and could cause the market price of our common stock to decline.Developing new products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other products we are developing.We have enhancements to our current Afirma offering and other diagnostic solutions under development that will require us to devote
Additional funds may not be available on terms that are favorable to us, or at all.If we are unable to develop products to keep pace with rapid technological, medical and scientific change, our operating results and competitive position could be harmed.In recent years, there have been numerous advances in technologies relating to diagnostics, particularly diagnostics that are based on
significant costs and expenses that could adversely affect our business, operating results, or financial condition.28Table of ContentsOur inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new solutions and technologies and expand our
In addition, we may have to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to our company.Risks Related to Being a Public CompanyWe will incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating
include:•actual or anticipated variations in our and our competitors' results of operations;•announcements by us or our competitors of new products, commercial relationships or capital commitments;30Table of Contents•changes in reimbursement by current or potential payers;•issuance of new securities analysts' reports or changed recommendations for our stock;•periodic fluctuations in our revenue, due in part to the way in which we recognize revenue;•actual or anticipated changes in regulatory oversight of our products;•developments or disputes concerning our intellectual property or other proprietary rights;•commencement of, or our involvement in, litigation;•announced or completed acquisitions of businesses or technologies by us or our competitors;•any major change in our management; and•general economic conditions and slow or negative growth of our markets.In
Forward-looking statements include, but are not limited to, statements about:•our ability to continue to increase adoption of and obtain reimbursement for Afirma;•anticipated trends and challenges in our business and the competition that we face;•the execution of our business plan and our growth strategy;•our expectations regarding the size of and growth in potential markets;•changes in laws or regulations applicable to our business, including potential regulation by the FDA;•our strategic relationships, collaboration and co-promotion efforts;•our ability to develop and commercialize new products and the timing of commercialization;•the outcome or success of clinical studies;•our liquidity and working capital requirements, including our long-term future cash requirements beyond the next
personnel-related costs and costs of operating as a public company), and for working capital and other general corporate purposes.The expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and
addition, other income (expense), net in 2011 includes $0.1 million we received from Genzyme in exchange for exclusive rights to negotiate a co-promotion agreement.Critical Accounting Polices and EstimatesOur management's discussion and analysis of our financial condition and results of operations is based on our financial statements,